Novo Nordisk’s Medicare Bridge Mixes Clinical Muscle with a Buyback Boost
The Medicare GLP-1 Bridge program that opens on July 1, 2026, hands Novo Nordisk a potential turning point…
Novo Nordisk’s Clinical Momentum Collides with Stubborn Share Price as Longevity Ambitions Take Sh
Semaglutide shows 52% sleep apnea risk reduction and anti-aging signals, but Novo Nordisk shares remain down 44% amid…
Novo Nordisk Juggles Lilly’s Clinical Challenge and Wegovy’s Indian Opportunity
Novo Nordisk’s stock barely moves as Eli Lilly’s superior trial data pressures GLP-1 business, but India’s Wegovy approval…
Novo Nordisk’s Double Play: Digital Authority Meets Clinical Depth as Semaglutide’s Reach Widens
Wegovy tops AI searches; semaglutide shows 63% MASH resolution; oral pill gains momentum. Novo Nordisk faces mixed Q1…
Novo Nordisk’s Strategic Pivot Gains Traction as Clinical Data and Analyst Forecast Align
Novo Nordisk divests last cell therapy asset to double down on obesity; new data shows Wegovy’s 28% weight…
Novo Nordisk’s Comeback Narrative Gains Steam from Analyst Upgrade, Clinical Data and Canadian Acc
Novo Nordisk shares surge 31% from March lows as Hedgeye forecasts 52-117% upside, fueled by oral obesity drug…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk’s Clinical Edge and US Push Battle a Steep Share Decline
Novo Nordisk posts strong clinical data and expands Wegovy, yet shares are down 22% YTD. Can its May…
Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model
Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain…